Research programme: hepatocyte nuclear factor 4 modulators - Ligand Pharmaceuticals
Latest Information Update: 19 Sep 2006
Price :
$50 *
At a glance
- Originator Ligand Pharmaceuticals
- Developer Eli Lilly and Company; Ligand Pharmaceuticals
- Class
- Mechanism of Action Hepatocyte nuclear factor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Metabolic disorders; Type 2 diabetes mellitus